Geographic Atrophy Clinical Trials in Austin, Texas
8 recruitingAustin, Texas
Showing 1–8 of 8 trials
Recruiting
Phase 2
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Geographic AtrophyMacular Degeneration
Janssen Research & Development, LLC274 enrolled104 locationsNCT06635148
Recruiting
Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age related macular degeneration (AMD)Geographic Atrophy (GA)
Regeneron Pharmaceuticals975 enrolled216 locationsNCT06541704
Recruiting
Phase 1
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Geographic Atrophy (GA)
Regeneron Pharmaceuticals54 enrolled5 locationsNCT07230834
Recruiting
Phase 1Phase 2
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy
Sanofi104 enrolled17 locationsNCT07215234
Recruiting
Phase 2
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Geographic Atrophy secondary to Age Related Macular Degeneration
ADARx Pharmaceuticals, Inc.240 enrolled24 locationsNCT06990269
Recruiting
Phase 2
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
Geographic Atrophy
Genentech, Inc.60 enrolled17 locationsNCT05626114
Recruiting
Phase 2
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Geographic Atrophy secondary to Age Related Macular Degeneration
Apellis Pharmaceuticals, Inc.240 enrolled43 locationsNCT07215390
Recruiting
Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Geographic Atrophy
Hoffmann-La Roche132 enrolled16 locationsNCT06961370